Lovastatin

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
Line 1: Line 1:
-
<applet load="" size="480" color="" frame="true" spin="on" Scene ="Lovastatin/Lovastatin/1" align="right" caption="Lovastatin, also known as Mevacor"/>
+
<applet load="" size="[450,380]" color="" frame="true" spin="on" Scene ="Lovastatin/Lovastatin/1" align="right" caption="Lovastatin, also known as Mevacor"/>
===Better Known as: Mevacor===
===Better Known as: Mevacor===
* Marketed By: Merck & Co. <br />
* Marketed By: Merck & Co. <br />
Line 13: Line 13:
===Pharmacokinetics===
===Pharmacokinetics===
-
{| class="wikitable" border="1" width="48%" style="text-align:center"
+
<table style="background: cellspacing="0px" align="" cellpadding="0px" width="42%">
-
|-
+
<tr>
-
! colspan="7" align="center"| Statin [[Pharmacokinetics]] at 10mg Dosage.<ref>PMID:11907637</ref><ref>PMID:15198967</ref><ref>PMID:12686673</ref><ref>PMID:18176327</ref><ref>PMID: 17452418</ref><ref>PMID:12895195</ref>
+
<td style="width:100%; vertical-align:top;border-width:0px; border-style:inset">
-
|-
+
<div style="height:100%; width: 100%">
-
! Parameter
+
{{:Statin Pharmacokinetics}}
-
! [[Atorvastatin]] (Lipitor)
+
</div>
-
! [[Fluvastatin]] (Lescol)
+
</td>
-
! [[Lovastatin]] (Mevacor)
+
</tr>
-
! [[Simvastatin]] (Zocor)
+
</table>
-
! [[Rosuvastatin]] (Crestor)
+
-
! [[Cerivastatin]] (Baycol)
+
-
|-
+
-
! [[Pharmacokinetics#Tmax|T<sub>max</sub>]] (hr)
+
-
! 2.5
+
-
! 1
+
-
! 3
+
-
! 1.5
+
-
! 4
+
-
! 1.5
+
-
|-
+
-
! [[Pharmacokinetics#Cmax|C<sub>max</sub>]] (ng/ml)
+
-
! 27-66
+
-
! 448
+
-
! 10-20
+
-
! 7.3
+
-
! 4.34
+
-
! 3.43
+
-
|-
+
-
! [[Pharmacokinetics#Bioavailability_.28F.29|Bioavailability]] (%)
+
-
! 12
+
-
! 19-29
+
-
! 5
+
-
! 5
+
-
! 20
+
-
! 60
+
-
|-
+
-
! [[Pharmacokinetics#Protein_Binding|Protein Binding]] (%)
+
-
! 80-90
+
-
! 99
+
-
! 95
+
-
! 95
+
-
! 88
+
-
! 99
+
-
|-
+
-
! [[Pharmacokinetics#Half_Life_.28T1.2F2.29|T<sub>1/2</sub>]] (hr)
+
-
! 15-30
+
-
! 2
+
-
! 3
+
-
! 2.7
+
-
! 19
+
-
! 2.2
+
-
|-
+
-
! [[Pharmacokinetics#Area_Under_the_Curve_.28AUC.29|AUC]] (ng/ml/hr)
+
-
! 104
+
-
! ~150
+
-
! 33
+
-
! 125
+
-
! 48
+
-
! 14.5
+
-
|-
+
-
! [[Pharmacokinetics#Inhibitory_Concentration_.28IC50.29|IC<sub>50</sub>]] (nM)
+
-
! 154
+
-
! 198
+
-
! 800-4200
+
-
! 66
+
-
! 320
+
-
! 50-90
+
-
|-
+
-
! Equivalent LDL Reduction Dosage (mg)
+
-
! 10
+
-
! --
+
-
! 80
+
-
! 20
+
-
! 5
+
-
! --
+
-
|-
+
-
! Metabolism
+
-
! Hepatic <br/>(CYP3A4)
+
-
! Hepatic <br/>(CYP2C9)
+
-
! Hepatic <br/>(CYP3A4)
+
-
! Hepatic <br/>(CYP3A4)
+
-
! Not <br/>Metabolized
+
-
! Hepatic <br />(CYP2C8)
+
-
|}
+
===References===
===References===

Revision as of 08:58, 10 December 2010

Lovastatin, also known as Mevacor

Drag the structure with the mouse to rotate

Better Known as: Mevacor

  • Marketed By: Merck & Co.
  • Major Indication: Hyperlipidemia & High Cholesterol (Hypercholesterolemia)
  • Drug Class: HMGR Inhibitor or Statin
  • Date of FDA Approval (Patent Expiration): 1991 (2001)
  • 2000 Sales: $520 Million
  • Importance: Was the first HMG-CoA Inhibitor. Statins are so ubiquitous, doctors have even suggested handing them out with fast food. See: the article
  • See Pharmaceutical Drugs for more information about other drugs and disorders

Mechanism of Action

Lovastatin is rapidly hydrolyzed in vivo into its corresponding b-hydroxyacid, which is an inhibitor of HMG-CoA Reductase (HMGR), a highly regulated enzyme responsible for the committed step in cholesterol synthesis. Lovastatin outcompetes HMG-CoA, the substrate of HMGR, in binding to HMGR.[1]

Pharmacokinetics

Statin Pharmacokinetics at 10mg Dosage
Parameter Atorvastatin (Lipitor) Fluvastatin (Lescol) Lovastatin (Mevacor) Simvastatin (Zocor) Rosuvastatin (Crestor) Cerivastatin (Baycol)
Tmax (hr) 2.5 1 3 1.5 4 1.5
Cmax (ng/ml) 27-66 448 10-20 7.3 4.34 3.43
Bioavailability (%) 12 19-29 5 5 20 60
Protein Binding (%) 80-90 99 95 95 88 99
T1/2 (hr) 15-30 2 3 2.7 19 2.2
AUC (ng/ml/hr) 104 ~150 33 125 48 14.5
IC50 (nM) 154 198 800 66 320 50-90
Equivalent LDL Reduction Dosage (mg) 10 -- 80 20 5 --
Metabolism Hepatic
(CYP3A4)
Hepatic
(CYP2C9)
Hepatic
(CYP3A4)
Hepatic
(CYP3A4)
None Hepatic
(CYP2C8)

For References, See References

References

  1. Corsini A, Maggi FM, Catapano AL. Pharmacology of competitive inhibitors of HMG-CoA reductase. Pharmacol Res. 1995 Jan;31(1):9-27. PMID:7784310


Proteopedia Page Contributors and Editors (what is this?)

David Canner, Alexander Berchansky

Personal tools